0000000000067715

AUTHOR

Giuseppe Pacileo

0000-0001-5965-6184

showing 2 related works from this author

Preoperative evaluation before MitraClip®: present and future perspective.

2014

ABSTRACT  Mitral regurgitation (MR) is the second most common heart valve disease worldwide. Currently, the management of MR is based on medical therapy (including biventricular pacing), surgery (mitral valve replacement or repair) and percutaneous therapy. However, in spite of guideline recommendations, 50% of individuals assessed in the Euro Heart Survey were not referred to surgical intervention due to comorbidities or real or perceived high risks for cardiac surgery; thus, in recent years, the focus of research has shifted to the development of percutaneous approaches to treat severe MR in order to restore valve function in a minimally invasive fashion. Among these techniques, the perc…

Heart Valve Prosthesis ImplantationMitral regurgitationmedicine.medical_specialtyPercutaneousbusiness.industrymedicine.medical_treatmentMitraClipPatient SelectionMitral valve replacementMitral Valve InsufficiencyGuidelineSurgeryCardiac surgerymedicine.anatomical_structureHeart Valve ProsthesisPreoperative CaremedicineMolecular MedicineHumansMitral ValveHeart valveCardiology and Cardiovascular MedicinebusinessPercutaneous Mitral Valve Repair
researchProduct

Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design

2022

Abstract Purpose Clinical practice forces the necessity to conduct a clinical trial concerning the group of outpatients with chronically advanced heart failure in III or IV NYHA functional class, frequently requiring hospitalizations due to HF exacerbation, and often left without any additional therapeutic option. The current trial aims to determine the efficacy and safety of repeated levosimendan infusions in the group of severe outpatients with reduced ejection fraction (HFrEF). Material and methods LEIA-HF (LEvosimendan In Ambulatory Heart Failure Patients) is a multicentre, randomized, double-blind, placebo-controlled, phase 4 clinical trial to determine whether the repetitive use of le…

Heart Failuremedicine.medical_specialtyCardiotonic AgentsEjection fractionExacerbationbusiness.industryStroke VolumeGeneral MedicineLevosimendanPlacebomedicine.diseaseClinical trialTreatment OutcomeDouble-Blind MethodHeart failureEmergency medicineAmbulatoryClinical endpointmedicineHumansbusinessSimendanmedicine.drugAdvances in Medical Sciences
researchProduct